Sikarin PCL
Sikarin PCL is a pharmaceutical company that develops, produces, and distributes generic and branded drugs, primarily in the Thai market, generating revenue through product sales and licensing agreements.
Business. Sikarin PCL (SKR.BK) is a healthcare company engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sikarin PCL (SKR.BK) is a healthcare company engaged in pharmaceutical activities within the Healthcare Facilities & Services industry. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand (SET). Specific details regarding operating segments and geographic revenue mix are not available.
Sikarin maintains a strong capital structure with a debt-to-equity ratio of 0.08, indicating a conservative leverage position relative to the industry median of 0.15. The company's liquidity is assessed as medium, with a current ratio of 3.44, which is above the industry median of 2.8. However, the firm's cash and equivalents of 50 million THB are significantly lower than its long-term debt of 609 million THB, resulting in a net cash deficit.
Profitability metrics show a return on equity (ROE) of 9.62% and a return on assets (ROA) of 7.87%, both exceeding the industry medians of 7.2% and 5.8%, respectively. The company's gross margin of 30.1% is in line with the industry median of 30.5%, but its operating margin of 16.2% is slightly below the median of 17.3%, suggesting potential inefficiencies in cost management.
Geographically, Sikarin's revenue is heavily concentrated in Thailand, with no disclosed international operations. The company operates in a single business segment focused on pharmaceuticals, with no material diversification across product lines or geographic regions.
Looking ahead, Sikarin is projected to grow revenue by 4.2% in the current fiscal year and 3.8% in the next, driven by expansion in its generic drug portfolio and increased market penetration. However, the company's capital expenditure of -379 million THB indicates a reduction in investment, which may limit long-term growth potential.
The company faces moderate risk from liquidity constraints, as its cash reserves are insufficient to cover long-term obligations. While dilution risk is currently low, the firm's net cash deficit and potential need for external financing could increase dilution pressure in the future. No recent dilutive events have been disclosed, and the company has not issued new shares in the past 12 months.
No recent material events, such as regulatory actions, earnings calls, or major business developments, have been disclosed in the latest filings or transcripts. The company's ESG score of 49.04 and a governance score of 32.77 suggest room for improvement in corporate governance practices.
- Sikarin has a strong ROE and ROA, outperforming industry medians.
- The company's liquidity position is medium, with a current ratio of 3.44.
- Revenue is concentrated in Thailand, with no international diversification.
- Capital expenditure is negative, indicating reduced investment in growth.
- ESG scores are below average, particularly in governance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Sikarin PCL Market data — financials · 2026-05-29
- Sikarin PCL Market data — ESG · 2026-05-29